Release – Tonix Pharmaceuticals to Present at the 2022 Q2 Investor Summit



Tonix Pharmaceuticals to Present at the 2022 Q2 Investor Summit

Research, News, and Market Data on Tonix Pharmaceuticals

 

CHATHAM, N.J., April 28, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the 2022 Q2 Investor Summit on Wednesday, May 4, 2022, at 11:00 a.m. ET at the Westin New York Grand Central, New York, NY.

Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com.

About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
2TNX-2900 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
3TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
4TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. 
5TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
6TNX-102 SL is an investigational new drug and has not been approved for any indication.
7TNX-1300 is an investigational new biologic and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Release – 1-800-FLOWERS.COM Inc. Reports Results for Its Fiscal 2022 Third Quarter



1-800-FLOWERS.COM, Inc. Reports Results for Its Fiscal 2022 Third Quarter

Research, News, and Market Data on 1-800-FLOWERS.COM

 

  • Total net revenues for the quarter were $469.6 million, down 1.0 percent compared with $474.2 million in the prior year period. Compared with the Company’s fiscal 2020 third quarter, prior to the pandemic, revenues were up 68.4 percent.
  • Net loss for the quarter was $23.4 million, or a loss of $0.36 per share compared with net income of $1.4 million, or $0.02 per diluted share, in the prior year period, primarily reflecting significant year-over-year cost increases for inbound and outbound shipping, labor, and digital marketing. Adjusted net loss1 for the quarter was $21.0 million, or a loss of $0.32 per share, compared with adjusted net income1 of $1.5 million, or $0.02 per diluted share, in the prior year period.
  • Adjusted EBITDA1 for the quarter was a loss of $12.0 million, compared with adjusted EBITDA1 of $15.4 million in the prior year period.
  • Company provides revised full-year guidance including revenue growth of 3.0 percent to 5.0 percent, adjusted EBITDA in a range of $110.0 million-to-$115.0 million and adjusted EPS in a range of $0.55 -to- $0.60 per diluted share.

(1 Refer to “Definitions of Non-GAAP Financial Measures” and the tables attached at the end of this press release for a reconciliation of non-GAAP results to applicable GAAP results.)

JERICHO, N.Y.–(BUSINESS WIRE)– 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS), today reported results for its fiscal 2022 third quarter ended March 27, 2022.

Chris McCann, CEO of 1-800-FLOWERS.COM, Inc., said, “Our results for the fiscal third quarter were below our expectations. A solid Valentine’s Day holiday for our 1-800-Flowers brand was offset by overall slower consumer demand for everyday gifting occasions throughout the period. These results reflected a continuation, and in some areas an escalation, of the macro-economic cost headwinds that we discussed back in January at the start of the quarter, combined with slower consumer demand reflecting growing consumer concerns with rapidly rising inflation and geopolitical unrest.

“While total revenues for the quarter were essentially flat with the prior year period, they were up more than 68 percent compared with our fiscal 2020 third quarter. Over the past three years we have essentially doubled our revenues to more than 
$2 billion and we anticipate driving further growth in the current fiscal fourth quarter and for the full year by leveraging our large customer file, the strong growth we continue to see in our Celebrations Passport loyalty program – which has grown more than 40 percent since the beginning of the current fiscal year – as well as initiatives in new innovative products and partnerships,” he said.

In terms of bottom-line results, McCann said that while the Company anticipates facing continued cost headwinds in the near term, “Our strong balance sheet enables us to invest in our operating platform, including investments to automate warehouse and distribution facilities, optimize our outbound shipping operations and build and bring in inventory early. Over the longer term, we anticipate these initiatives will enable us to improve our gross margins and drive enhanced bottom-line performance.”

McCann added, “Looking ahead, the current macroeconomy is highly unpredictable, with rising inflation and other factors impacting both costs and consumer demand. However, it is important to note that we have faced challenging macro market conditions in the past and, because of the strength of our unique business platform, combined with our talented and experienced team across the enterprise, we have emerged a bigger, better, and stronger company, and we are confident that we will continue to grow our company and build shareholder value over the long term.”

Third Quarter 2022 Financial Results

Total consolidated net revenues were 
$469.6 million, down 1.0 percent compared with 
$474.2 million in the prior year period. Compared with the Company’s fiscal 2020 third quarter, prior to the pandemic, revenues were up 68.4 percent.

Gross profit margin for the quarter was 32.8 percent, a decline of 610 basis points compared with 38.9 percent in the prior year period, primarily reflecting increased costs for inbound and outbound shipping, labor, and write-offs of expired perishable inventory. Operating expenses as a percent of total revenues, improved 60 basis points to 38.4 percent of total sales, compared with 39.0 percent in the prior year period. Operating expenses, excluding stock-based compensation, the costs associated with a one-time employee class action legal settlement, and appreciation-or-depreciation of investments in the Company’s non-qualified compensation plan, improved 10 basis points to 38.1 percent of total sales, compared with 38.2 percent in the prior year period.

The combination of these factors resulted in a net loss for the quarter of 
$23.4 million, or (
$0.36) per share compared with net income of 
$1.4 million, or 
$0.02 per diluted share, in the prior year period. Adjusted net loss1 for the quarter was 
$21.0 million, or (
$0.32) per share, compared with adjusted net income1 of 
$1.5 million, or 
$0.02 per diluted share, in the prior year period. Adjusted EBITDA1 for the quarter was a loss of 
$12.0 million, compared with adjusted EBITDA1 of 
$15.4 million in the prior year period.

Segment Results:

The Company provides selected financial results for its Gourmet Foods and Gift Baskets, Consumer Floral and Gifts, and BloomNet® segments in the tables attached to this release and as follows:

  • Gourmet Foods and Gift Baskets: Revenues for the quarter were 
    $167.4 million, down 4.5 percent compared with 
    $175.2 million in the prior year period primarily reflecting the shift of the Easter holiday later into the Company’s fiscal fourth quarter as well as lower deferred revenue entering the quarter, compared with the prior year period, partly offset by higher year-over-year wholesale revenues and revenues associated with Vital Choice®, which the Company acquired in October, 2021. Gross profit margin was 25.3 percent, a decline of 1,410 basis points compared with 39.4 percent in the prior year period, primarily reflecting increased costs for labor, inbound and outbound shipping and charges associated with the write-off of expiring inventories. Segment contribution margin1 was a loss of 
    $17.1 million compared with segment contribution margin of 
    $12.1 million in the prior year period, reflecting the reduced revenues and gross margin and higher year-over-year digital marketing costs. Adjusted segment contribution margin1 for the quarter was a loss of 
    $14.2 million excluding one-time costs associated with the settlement of an employee class action lawsuit.
  • Consumer Floral and Gifts: Total revenues in this segment were 
    $264.2 million, an increase of 1.5 percent compared to 
    $260.4 million in the prior year period, primarily reflecting solid growth for the Valentine’s Day holiday partly offset by softer everyday gifting sales. Gross profit margin was 36.7 percent, down 110 basis points compared with 37.8 percent in the prior year period primarily reflecting increased shipping costs. Segment contribution margin1 was 
    $20.5 million, down 8.9 percent compared with 
    $22.5 million in the prior year period, primarily reflecting the reduced gross margin and higher year-over-year digital marketing costs.
  • BloomNet: Revenues for the quarter were 
    $38.4 million, down 1.0 percent compared with 
    $38.8 million in the prior year period. Gross profit margin was 38.7 percent, down 560 basis points, compared with 44.3 percent in the prior year period, primarily reflecting higher inbound shipping costs and product mix. As a result, segment contribution margin1 was 
    $9.8 million, down 18.8 percent compared with 
    $12.0 million in the prior year period.

Company Guidance

The Company is updating its guidance for fiscal year 2022 year reflecting reported results for the first three quarters of the year as well as its outlook for the remainder of the year. The updated guidance includes:

  • Total revenue growth of 3.0 percent to 5.0 percent, compared with the prior year;
  • Adjusted EBITDA in a range of 
    $110.0 million-to-
    $115.0 million;
  • Adjusted EPS in a range of 
    $0.55 -to- 
    $0.60 per diluted share, and;
  • The Company anticipates that Free Cash Flow for the year will be down significantly compared with the prior year based on its updated guidance and its plans to use its strong balance sheet to invest in inventory to support its growth plans and address the headwinds it sees in the macro economy.

The Company’s guidance for the year is based on several factors, including,

  • The continuing headwinds associated with the ongoing pandemic, increased costs for labor, inbound and outbound shipping and marketing, as well as consumer concerns regarding rising price inflation and geopolitical issues, somewhat offset by:
  • the Company’s ability to continue to attract new customers and add new members to its Celebrations Passport® Loyalty program, which is helping drive increased frequency, retention, and cross-category/ cross-brand purchases.

Definitions of non-GAAP Financial Measures:

We sometimes use financial measures derived from consolidated financial information, but not presented in our financial statements prepared in accordance with 
U.S. generally accepted accounting principles(“GAAP”). Certain of these are considered “non-GAAP financial measures” under the 
U.S. Securities and Exchange Commission rules. Non-GAAP financial measures referred to in this document are either labeled as “non-GAAP” or designated as such with a “1”. See below for definitions and the reasons why we use these non-GAAP financial measures. Where applicable, see the Selected Financial Information below for reconciliations of these non-GAAP measures to their most directly comparable GAAP financial measures.

EBITDA and Adjusted EBITDA:

We define EBITDA as net income (loss) before interest, taxes, depreciation, and amortization. Adjusted EBITDA is defined as EBITDA adjusted for the impact of stock-based compensation, Non-Qualified Plan Investment appreciation/depreciation, and for certain items affecting period-to-period comparability. See Selected Financial Information for details on how EBITDA and adjusted EBITDA were calculated for each period presented. The Company presents EBITDA and adjusted EBITDA because it considers such information meaningful supplemental measures of its performance and believes such information is frequently used by the investment community in the evaluation of similarly situated companies. The Company uses EBITDA and adjusted EBITDA as factors to determine the total amount of incentive compensation available to be awarded to executive officers and other employees. The Company’s credit agreement uses EBITDA and adjusted EBITDA to determine its interest rate and to measure compliance with certain covenants. The Company also uses EBITDA and adjusted EBITDA to evaluate and price potential acquisition candidates. EBITDA and adjusted EBITDA have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. Some of the limitations are: (a) EBITDA and adjusted EBITDA do not reflect changes in, or cash requirements for, the Company’s working capital needs; (b) EBITDA and adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on the Company’s debts; and (c) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and EBITDA does not reflect any cash requirements for such capital expenditures. EBITDA and adjusted EBITDA should only be used on a supplemental basis combined with GAAP results when evaluating the Company’s performance.

Segment Contribution Margin and Adjusted Segment Contribution Margin:

We define segment contribution margin as earnings before interest, taxes, depreciation, and amortization, before the allocation of corporate overhead expenses. Adjusted segment contribution margin is defined as segment contribution margin adjusted for certain items affecting period-to-period comparability. See Selected Financial Information for details on how segment contribution margin and adjusted segment contribution margin was calculated for each period presented. When viewed together with our GAAP results, we believe segment contribution margin and adjusted segment contribution margin provide management and users of the financial statements with meaningful information about the performance of our business segments. Segment contribution margin and adjusted segment contribution margin are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. The material limitation associated with the use of the segment contribution margin and adjusted segment contribution margin is that they are an incomplete measure of profitability as they do not include all operating expenses or non-operating income and expenses. Management compensates for these limitations when using this measure by looking at other GAAP measures, such as operating income and net income.

Adjusted Net Income (Loss) and Adjusted or Comparable Net Income (Loss) Per Common Share:

We define adjusted net income (loss) and adjusted or comparable net income (loss) per common share as net income (loss) and net income (loss) per common share adjusted for certain items affecting period-to-period comparability. See Selected Financial Information below for details on how adjusted net income (loss) and adjusted or comparable net income (loss) per common share were calculated for each period presented. We believe that adjusted net income (loss) and adjusted or comparable net income (loss) per common share are meaningful measures because they increase the comparability of period-to-period results. Since these are not measures of performance calculated in accordance with GAAP, they should not be considered in isolation of, or as a substitute for, GAAP net income (loss) and net income (loss) per common share, as indicators of operating performance and they may not be comparable to similarly titled measures employed by other companies.

Free Cash Flow:

We define free cash flow as net cash provided by operating activities less capital expenditures. The Company considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after the purchases of fixed assets, which can then be used to, among other things, invest in the Company’s business, make strategic acquisitions, strengthen the balance sheet, and repurchase stock or retire debt. Free cash flow is a liquidity measure that is frequently used by the investment community in the evaluation of similarly situated companies. Since free cash flow is not a measure of performance calculated in accordance with GAAP, it should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. A limitation of the utility of free cash flow as a measure of financial performance is that it does not represent the total increase or decrease in the company’s cash balance for the period.

About 1-800-FLOWERS.COM, Inc.

1-800-FLOWERS.COM, Inc. is a leading provider of gifts designed to help customers express, connect, and celebrate. The Company’s e-commerce business platform features an all-star family of brands, including: 1-800-Flowers.com®, 1-800-Baskets.com®, Cheryl’s Cookies®, Harry & David®, PersonalizationMall.com®, Shari’s Berries®, FruitBouquets.com®, Moose Munch®, The Popcorn Factory®, Wolferman’s Bakery®, Vital Choice®, Stock Yards® and Simply Chocolate®. Through the Celebrations Passport® loyalty program, which provides members with free standard shipping and no service charge across our portfolio of brands, 1-800-FLOWERS.COM, Inc. strives to deepen relationships with customers. The Company also operates BloomNet®, an international floral and gift industry service provider offering a broad range of products and services designed to help members grow their businesses profitably; Napco?, a resource for floral gifts and seasonal décor; DesignPac Gifts, LLC, a manufacturer of gift baskets and towers; and Alice’s Table®, a lifestyle business offering fully digital livestreaming floral, culinary and other experiences to guests across the country. 1-800-FLOWERS.COM, Inc. was recognized among the top five on the National Retail Federation’s 2021 Hot 25 Retailers list, which ranks the nation’s fastest-growing retail companies. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS. For more information, visit 1800flowersinc.com or follow @1800FLOWERSInc on Twitter.

FLWS-COMP / FLWS-FN

Special Note Regarding Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties, and other factors, many of which are outside of the Company’s control, which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to, statements regarding the Company’s ability to achieve its updated guidance for fiscal-year 2022; the impact of the Covid-19 pandemic on the Company; its ability to successfully integrate acquired businesses and assets; its ability to successfully execute its strategic initiatives, including its investments in its operating platform; its ability to cost-effectively acquire and retain customers; the outcome of contingencies, including legal proceedings in the normal course of business; its ability to compete against existing and new competitors; its ability to manage expenses associated with sales and marketing and necessary general and administrative and technology investments; its ability to reduce promotional activities and achieve more efficient marketing programs; and general consumer sentiment and industry and economic conditions that may affect, among other things, the levels of discretionary customer purchases of the Company’s products and the costs of shipping and labor. Reconciliations for forward looking figures would require unreasonable efforts at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including for example those related to compensation, tax items, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. The lack of such reconciling information should be considered when assessing the impact of such disclosures. The Company undertakes no obligation to publicly update any of the forward-looking statements, whether because of new information, future events or otherwise, made in this release or in any of its SEC filings. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties. For a more detailed description of these and other risk factors, refer to the Company’s SEC filings, including the Company’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.

Conference Call:

The Company will conduct a conference call to discuss the above details and attached financial results today, Thursday, April 28, 2022, at 8:00 a.m. (ET). The conference call will be webcast live from the Investor Relations section of the Company’s website at www.1800flowersinc.com. A recording of the call will be posted on the Investor Relations section of the Company’s web site within two hours of the call’s completion. A replay of the call can be accessed beginning at 2:00 p.m. ET on the day of the call through May 5, 2022, at: (US) 1-877-344-7529; (
Canada) 855-669-9658; (International) 1-412-317-0088; enter conference ID #:5119258.

Note: The attached tables are an integral part of this press release without which the information presented in this press release should be considered incomplete.

1-800-FLOWERS.COM, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

 

 

March 27, 2022

 

 

June 27, 2021

 

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

93,025

 

 

$

173,573

 

Trade receivables, net

 

 

40,881

 

 

 

20,831

 

Inventories, net

 

 

214,444

 

 

 

153,863

 

Prepaid and other

 

 

33,506

 

 

 

51,792

 

Total current assets

 

 

381,856

 

 

 

400,059

 

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

230,067

 

 

 

215,287

 

Operating lease right-of-use assets

 

 

130,897

 

 

 

86,230

 

Goodwill

 

 

213,905

 

 

 

208,150

 

Other intangibles, net

 

 

146,641

 

 

 

139,048

 

Other assets

 

 

25,284

 

 

 

27,905

 

Total assets

 

$

1,128,650

 

 

$

1,076,679

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

 

$

58,502

 

 

$

57,434

 

Accrued expenses

 

 

176,551

 

 

 

178,512

 

Current maturities of long-term debt

 

 

20,000

 

 

 

20,000

 

Current portion of long-term operating lease liabilities

 

 

12,518

 

 

 

9,992

 

Total current liabilities

 

 

267,571

 

 

 

265,938

 

 

 

 

 

 

 

 

 

Long-term debt, net

 

 

147,171

 

 

 

161,512

 

Long-term operating lease liabilities

 

 

125,831

 

 

 

79,375

 

Deferred tax liabilities

 

 

32,484

 

 

 

34,162

 

Other liabilities

 

 

21,802

 

 

 

26,622

 

Total liabilities

594,859

 

 

 

567,609

 

Total stockholders’ equity

 

 

533,791

 

 

 

509,070

 

Total liabilities and stockholders’ equity

 

$

1,128,650

 

 

$

1,076,679

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

Consolidated Statements of Operations

(in thousands, except for per share data)

(unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 27,
2022

 

 

March 28,
2021

 

 

March 27,
2022

 

 

March 28,
2021

 

Net revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

E-Commerce

 

$

409,777

 

 

$

424,768

 

 

$

1,500,670

 

 

$

1,441,441

 

Other

 

 

59,799

 

 

 

49,466

 

 

 

221,323

 

 

 

193,821

 

Total net revenues

 

 

469,576

 

 

 

474,234

 

 

 

1,721,993

 

 

 

1,635,262

 

Cost of revenues

 

 

315,485

 

 

 

289,535

 

 

 

1,063,938

 

 

 

936,837

 

Gross profit

 

 

154,091

 

 

 

184,699

 

 

 

658,055

 

 

 

698,425

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and sales

 

 

130,645

 

 

 

127,923

 

 

 

432,795

 

 

 

402,904

 

Technology and development

 

 

14,456

 

 

 

14,281

 

 

 

41,369

 

 

 

39,937

 

General and administrative

 

 

22,553

 

 

 

30,912

 

 

 

78,491

 

 

 

89,960

 

Depreciation and amortization

 

 

12,693

 

 

 

11,892

 

 

 

36,251

 

 

 

31,792

 

Total operating expenses

 

 

180,347

 

 

 

185,008

 

 

 

588,906

 

 

 

564,593

 

Operating income (loss)

 

 

(26,256)

 

 

 

(309

)

 

 

69,149

 

 

 

133,832

 

Interest expense, net

 

 

1,226

 

 

 

1,553

 

 

 

4,477

 

 

 

4,520

 

Other (income) expense, net

 

 

4,007

 

 

 

(945

)

 

 

954

 

 

 

(4,201)

Income (loss) before income taxes

 

 

(31,489)

 

 

 

(917

)

 

 

63,718

 

 

 

133,513

 

Income tax expense (benefit)

 

 

(8,080)

 

 

 

(2,344

)

 

 

11,858

 

 

 

28,171

 

Net income (loss)

 

$

(23,409)

 

 

$

1,427

 

 

$

51,860

 

 

$

105,342

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income (loss) per common share

 

$

(0.36)

 

 

$

0.02

 

 

$

0.80

 

 

$

1.63

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income (loss) per common share

 

$

(0.36)

 

 

$

0.02

 

 

$

0.79

 

 

$

1.58

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in the calculation of net income (loss) per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

65,028

 

 

 

64,885

 

 

 

65,086

 

 

 

64,644

 

Diluted

 

 

65,028

 

 

 

66,474

 

 

 

65,849

 

 

 

66,564

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Nine months ended

 

 

March 27, 2022

 

March 28, 2021

 

 

 

 

 

 

Operating activities:

 

 

 

 

Net income

$

51,860

 

$

105,342

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

36,251

 

 

31,792

 

Amortization of deferred financing costs

 

943

 

 

844

 

Deferred income taxes

 

(1,678)

 

 

(2,131)

 

Bad debt expense

 

(873)

 

 

959

 

Stock-based compensation

 

6,803

 

 

8,229

 

Other non-cash items

 

1,352

 

 

(79)

 

Changes in operating items:

 

 

 

 

Trade receivables

 

(18,570)

 

 

(23,520)

 

Inventories

 

(51,928)

 

 

(7,627)

 

Prepaid and other

 

7,174

 

 

(1,301)

 

Accounts payable and accrued expenses

 

6,847

 

 

96,947

 

Other assets and liabilities

 

547

 

 

8,756

 

Net cash provided by operating activities

 

38,728

 

 

218,211

 

 

 

 

 

 

Investing activities:

 

 

 

 

Acquisitions, net of cash acquired

 

(22,105)

 

 

(250,943)

 

Capital expenditures, net of non-cash expenditures

 

(47,945)

 

 

(26,821)

 

Purchase of equity investments

 

 

 

(1,251)

 

Net cash used in investing activities

 

(70,050)

 

 

(279,015)

 

 

 

 

 

 

Financing activities:

 

 

 

 

Acquisition of treasury stock

 

(34,788)

 

 

(14,825)

 

Proceeds from exercise of employee stock options

 

846

 

 

1,596

 

Proceeds from bank borrowings

 

125,000

 

 

265,000

 

Repayment of notes payable and bank borrowings

 

(140,000)

 

 

(172,497)

 

Debt issuance cost

 

(284)

 

 

(2,193)

 

Net cash provided by (used in) financing activities

 

(49,226)

 

 

77,081

 

 

 

 

 

 

Net change in cash and cash equivalents

 

(80,548)

 

 

16,277

 

Cash and cash equivalents:

 

 

 

 

Beginning of period

 

173,573

 

 

240,506

 

End of period

$

93,025

 

$

256,783

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information – Category Information

(dollars in thousands) (unaudited)

 

 

Three Months Ended

 

March 27, 2022

Vital Choice and
Alice’s Table
Transaction Costs

 

Litigation
Settlement

As Adjusted
(non-GAAP)
March 27, 2022

March 28, 2021

%
Change

Net revenues:

 

 

 

 

 

 

 

Consumer Floral & Gifts

$

264,243

 

$

$

$

264,243

 

 

$

260,393

 

1.5

%

BloomNet

 

38,448

 

 

 

 

38,448

 

 

 

38,833

 

-1.0

%

Gourmet Foods & Gift Baskets

 

167,402

 

 

 

 

167,402

 

 

 

175,245

 

-4.5

%

Corporate

 

43

 

 

 

 

43

 

 

 

54

 

-20.4

%

Intercompany eliminations

 

(560

)

 

 

 

(560

)

 

 

(291

)

-92.4

%

Total net revenues

$

469,576

 

$

$

$

469,576

 

 

$

474,234

 

-1.0

%

 

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

 

Consumer Floral & Gifts

$

96,875

 

$

$

$

96,875

 

 

$

98,397

 

-1.5

%

 

 

36.7

%

 

 

 

36.7

%

 

 

37.8

%

 

 

 

 

 

 

 

 

 

BloomNet

 

14,895

 

 

 

 

14,895

 

 

 

17,194

 

-13.4

%

 

 

38.7

%

 

 

 

38.7

%

 

 

44.3

%

 

 

 

 

 

 

 

 

 

Gourmet Foods & Gift Baskets

 

42,343

 

 

 

 

42,343

 

 

 

69,091

 

-38.7

%

 

 

25.3

%

 

 

 

25.3

%

 

 

39.4

%

 

 

 

 

 

 

 

 

 

Corporate

 

(22

)

 

 

 

(22

)

 

 

17

 

-229.4

%

 

 

-51.2

%

 

 

 

-51.2

%

 

 

31.5

%

 

 

 

 

 

 

 

 

 

Total gross profit

$

154,091

 

$

$

$

154,091

 

 

$

184,699

 

-16.6

%

 

 

32.8

%

 

 

 

32.8

%

 

 

38.9

%

 

EBITDA (non-GAAP):

 

 

 

 

 

 

 

Segment Contribution Margin (non-GAAP) (a):

 

 

 

Consumer Floral & Gifts

$

20,523

 

$

$

$

20,523

 

 

$

22,537

 

-8.9

%

BloomNet

 

9,783

 

 

 

 

9,783

 

 

 

12,042

 

-18.8

%

Gourmet Foods & Gift Baskets

 

(17,134

)

 

 

2,900

 

(14,234

)

 

 

12,132

 

-217.3

%

Segment Contribution Margin Subtotal

 

13,172

 

 

 

2,900

 

16,072

 

 

 

46,711

 

-65.6

%

Corporate (b)

 

(26,735

)

 

25

 

 

(26,710

)

 

 

(35,128

)

24.0

%

EBITDA (non-GAAP)

 

(13,563

)

 

25

 

2,900

 

(10,638

)

 

 

11,583

 

-191.8

%

Add: Stock-based compensation

 

1,507

 

 

 

 

1,507

 

 

 

2,871

 

-47.5

%

Add: Compensation charge related to NQ Plan Investment

Appreciation

 

(2,881

)

 

 

 

(2,881

)

 

 

916

 

-414.5

%

Adjusted EBITDA (non-GAAP)

$

(14,937

)

$

25

$

2,900

$

(12,012

)

 

$

15,370

 

-178.2

%

 

 

 

 

 

 

 

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information – Category Information

(dollars in thousands) (unaudited)

 

Nine Months Ended

March 27,
2022

Vital Choice
and Alice’s
Table
Transaction Costs

Litigation
Settlement

As Adjusted
(non-GAAP)
March 27,
2022

March 28,
2021

Personalization
Mall Litigation
& Transaction
Costs

Harry &
David Store
Closure
Costs

As Adjusted
(non-GAAP)
March 28,
2021

%
Change

Net revenues:

Consumer Floral & Gifts

$

760,555

 

$

$

$

760,555

 

$

727,296

 

$

$

 

$

727,296

 

4.6

%

BloomNet

 

107,212

 

 

107,212

 

 

105,622

 

 

105,622

 

1.5

%

Gourmet Foods & Gift Baskets

 

855,830

 

 

855,830

 

 

803,439

 

 

803,439

 

6.5

%

Corporate

 

157

 

 

157

 

 

295

 

 

295

 

-46.8

%

Intercompany eliminations

 

(1,761

)

 

 

 

(1,761

)

 

(1,390

)

 

 

 

(1,390

)

-26.7

%

Total net revenues

$

1,721,993

 

$

$

$

1,721,993

 

$

1,635,262

 

$

$

 

$

1,635,262

 

5.3

%

Gross profit:

Consumer Floral & Gifts

$

302,903

 

$

$

$

302,903

 

$

298,457

 

$

$

 

$

298,457

 

1.5

%

 

39.8

%

 

39.8

%

 

41.0

%

 

41.0

%

 

BloomNet

 

46,325

 

 

46,325

 

 

48,852

 

 

48,852

 

-5.2

%

 

43.2

%

 

43.2

%

 

46.3

%

 

46.3

%

 

Gourmet Foods & Gift Baskets

 

308,745

 

 

308,745

 

 

350,988

 

 

350,988

 

-12.0

%

 

36.1

%

 

36.1

%

 

43.7

%

 

43.7

%

 

Corporate

 

82

 

 

82

 

 

128

 

 

128

 

-35.9

%

 

52.2

%

 

52.2

%

 

43.4

%

 

43.4

%

 

 

 

 

 

 

 

 

Total gross profit

$

658,055

 

$

$

$

658,055

 

$

698,425

 

$

$

 

$

698,425

 

-5.8

%

 

38.2

%

 

 

 

38.2

%

 

42.7

%

 

 

 

 

42.7

%

EBITDA (non-GAAP):

Segment Contribution Margin (non-GAAP) (a)

Consumer Floral & Gifts

$

77,869

 

$

$

$

77,869

 

$

87,430

 

$

$

 

$

87,430

 

-10.9

%

BloomNet

 

32,530

 

 

32,530

 

 

34,604

 

 

34,604

 

-6.0

%

Gourmet Foods & Gift Baskets

 

85,695

 

 

 

2,900

 

88,595

 

 

145,172

 

 

 

(483

)

 

144,689

 

-38.8

%

Segment Contribution Margin Subtotal

 

196,094

 

 

 

2,900

 

198,994

 

 

267,206

 

 

 

(483

)

 

266,723

 

-25.4

%

Corporate (b)

 

(90,694

)

 

540

 

 

(90,154

)

 

(101,582

)

 

5,403

 

 

(96,179

)

-6.3

%

EBITDA (non-GAAP)

 

105,400

 

 

540

 

2,900

 

108,840

 

 

165,624

 

 

5,403

 

(483

)

 

170,544

 

-36.2

%

Add: Stock-based compensation

 

6,803

 

 

6,803

 

 

8,229

 

 

8,229

 

-17.3

%

Add: Compensation charge related to NQ

Plan Investment Appreciation

 

111

 

 

111

 

 

4,123

 

 

4,123

 

-97.3

%

Adjusted EBITDA (non-GAAP)

$

112,314

 

$

540

$

2,900

$

115,754

 

$

177,976

 

$

5,403

$

(483

)

$

182,896

 

-36.7

%

 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

(in thousands) (unaudited)

 

Reconciliation of net income to adjusted net income (loss) (non-GAAP):

Three Months Ended

Nine Months Ended

March 27,
2022

March 28,
2021

 

March 27,
2022

 

March 28,
2021

 

Net income (loss)

$

(23,409

)

$

1,427

$

51,860

 

$

105,342

 

Adjustments to reconcile net income (loss) to adjusted net income (loss) (non-GAAP)

Add: Transaction costs

 

25

 

 

 

540

 

 

5,403

 

Add: Litigation settlement

 

2,900

 

 

 

2,900

 

 

 

Deduct: Harry & David store closure cost adjustment

 

 

 

 

 

 

(483

)

Deduct: Income tax effect on adjustments

 

(533

)

 

79

 

(641

)

 

(1,038

)

Adjusted net income (loss) (non-GAAP)

$

(21,017

)

$

1,506

$

54,659

 

$

109,224

 

 

Basic and diluted net income (loss) per common share

Basic

$

(0.36

)

$

0.02

$

0.80

 

$

1.63

 

Diluted

$

(0.36

)

$

0.02

$

0.79

 

$

1.58

 

 
 

Basic and diluted adjusted net income (loss) per common share (non-GAAP)

Basic

$

(0.32

)

$

0.02

$

0.84

 

$

1.69

 

Diluted

$

(0.32

)

$

0.02

$

0.83

 

$

1.64

 

 

Weighted average shares used in the calculation of net income (loss) and adjusted net income (loss) per common share

Basic

 

65,028

 

 

64,885

 

65,086

 

 

64,644

 

Diluted

 

65,028

 

 

66,474

 

65,849

 

 

66,564

 

 
 

1-800-FLOWERS.COM, Inc. and Subsidiaries

Selected Financial Information

(in thousands) (unaudited)

 

Reconciliation of net income (loss) to adjusted EBITDA (non-GAAP):

Three Months Ended

Nine Months Ended

March 27,
2022

March 28,
2021

March 27,
2022

March 28,
2021

 

Net income (loss)

$

(23,409

)

$

1,427

 

$

51,860

$

105,342

 

Add: Interest expense, net

 

5,233

 

 

608

 

 

5,431

 

319

 

Add: Depreciation and amortization

 

12,693

 

 

11,892

 

 

36,251

 

31,792

 

Add: Income tax expense (benefit)

 

(8,080

)

 

(2,344

)

 

11,858

 

28,171

 

EBITDA

 

(13,563

)

 

11,583

 

 

105,400

 

165,624

 

Add: Stock-based compensation

 

1,507

 

 

2,871

 

 

6,803

 

8,229

 

Add: Compensation charge related to NQ plan investment appreciation

 

(2,881

)

 

916

 

111

4,123

Add: Transaction costs

 

25

 

 

 

 

540

 

5,403

 

Add: Litigation settlement

 

2,900

 

 

 

 

2,900

 

(483

)

Adjusted EBITDA

$

(12,012

)

$

15,370

 

$

115,754

$

182,896

 

 
 

(a) Segment performance is measured based on segment contribution margin or segment Adjusted EBITDA, reflecting only the direct controllable revenue and operating expenses of the segments, both of which are non-GAAP measurements. As such, management’s measure of profitability for these segments does not include the effect of corporate overhead, described above, depreciation and amortization, other income (net), and other items that we do not consider indicative of our core operating performance.

 

(b) Corporate expenses consist of the Company’s enterprise shared service cost centers, and include, among other items, Information Technology, Human Resources, Accounting and Finance, Legal, Executive and Customer Service Center functions, as well as Stock-Based Compensation. In order to leverage the Company’s infrastructure, these functions are operated under a centralized management platform, providing support services throughout the organization. The costs of these functions, other than those of the Customer Service Center, which are allocated directly to the above categories based upon usage, are included within corporate expenses as they are not directly allocable to a specific segment.

 

Investor Contact:

Joseph D. Pititto

(516) 237-6131

invest@1800flowers.com



Media Contact:

Kathleen Waugh

(516) 237-6028

kwaugh@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc.

Release – ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis ALS



ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

News and Market Data on ProMIS Neurosciences

 

TORONTO, Ontario and CAMBRIDGE, MA, April 28, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.

Almost all cases of ALS, and about half of cases of the related disease frontotemporal degeneration (FTD), feature intracellular aggregates of the protein TDP-43 in the brain and spinal cord. Although normal TDP-43 protein is critical for the survival of neurons, misfolded aggregates of TDP-43 possess many neurotoxic activities and are believed to be a driver of disease. Using its discovery platform, ProMIS generated high-affinity monoclonal antibodies that are selective for the misfolded, toxic form of TDP-43 and has nominated monoclonal antibody PMN267 as the lead candidate based on its binding profile and activity in cell systems. Recent data generated by two independent sources have now provided additional support for the therapeutic potential of PMN267.

Dr. Gene Yeo’s laboratory at the University of California San Diego has shown that an “intrabody” version of PMN267 delivered inside cells via a gene therapy vector significantly reduced the amount of misfolded TDP-43 aggregates in human motor neurons derived from ALS patients, the cell type predominantly affected in ALS.

In an aggressive mouse model of ALS/FTD conducted at a contract research organization, testing of PMN267 as an injectable antibody treatment also produced evidence for protection against disability. These results are in line with reports indicating that antibodies with effector function can be taken up inside neurons and trigger degradation of their target, in this case toxic TDP-43 aggregates.

ProMIS CSO Dr. Neil Cashman was pleased by the results, saying “these are encouraging findings that support the activity of PMN267 as a conventional antibody and as an intrabody constructed from PMN267”. Dr. Larry Altstiel, ProMIS’ CMO, said “this is promising work to be moved forward as rapidly as possible to address the tragic human disease ALS.”

ProMIS also notes the progress made in targeting another ALS/FTD target called RACK1 (receptor for activated C kinase 1). ProMIS’ encouraging preclinical data implicating RACK1 in ALS were presented recently as a poster at the American Academy of Neurology in Seattle, entitled “RACK1 Knockdown Alleviates TDP-43-Associated Global Translational Suppression in vitro and Neurodegeneration in vivo.”

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF

To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: ProMIS Neurosciences Inc.

Release – Entravision Schedules First Quarter 2022 Earnings Release and Conference Call



Entravision Schedules First Quarter 2022 Earnings Release and Conference Call

Research, News, and Market Data on Entravision

 

SANTA MONICA, Calif.–(BUSINESS WIRE)– Entravision (NYSE: EVC), a leading global advertising solutions, media and technology company, announced that it will release its first quarter 2022 financial results after market close on Thursday, May 5, 2022. The Company will host a conference call that day at 5:00 p.m. Eastern Time to discuss the first quarter 2022 results.

To access the conference call, please dial (877) 407-9716 (U.S.) or (201) 493-6779 (International) ten minutes prior to the start time. The call will also be available via live webcast on the investor relations portion of the Company’s website located at www.entravision.com.

If you cannot listen to the conference call at its scheduled time, there will be a replay available through Thursday, May 19, 2022 which can be accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International) and entering the passcode 13728063. The webcast will also be archived on the Company’s website.

About Entravision

Entravision is a leading global advertising, media and ad-tech solutions company connecting brands to consumers by representing top platforms and publishers. Our dynamic portfolio includes digital, television and audio offerings. Digital, our largest revenue segment, is comprised of four business units: our digital sales representation business; Smadex, our programmatic ad purchasing platform; our branding and mobile performance solutions business; and our digital audio business. Through our digital sales representation business, we connect global media companies such as Meta, Twitter, TikTok and Spotify with advertisers in primarily emerging growth markets worldwide. Smadex is our mobile-first demand side platform, enabling advertisers to execute performance campaigns using machine learning. We also offer a branding and mobile performance solutions business, which provides managed services to advertisers looking to connect with global consumers, primarily on mobile devices, and our digital audio business provides digital audio advertising solutions for advertisers in the Americas. In addition to digital, Entravision has 49 television stations and is the largest affiliate group of the Univision and UniMás television networks. Entravision also manages 46 primarily Spanish-language radio stations that feature nationally recognized, Emmy award-winning talent. Shares of Entravision Class A Common Stock trade on the NYSE under ticker: EVC. Learn more about our offerings at entravision.com or connect with us on LinkedIn and Facebook.

Christopher T. Young
Chief Financial Officer
Entravision
310-447-3870

Kimberly Esterkin
Addo Investor Relations
310-829-5400
evc@addo.com

Source: Entravision

Release – electroCore to Announce First Quarter 2022 Financial Results on May 5



electroCore to Announce First Quarter 2022 Financial Results on May 5

News and Market Data on electroCore

 

ROCKAWAY, N.J.
April 28, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended 
March 31, 2022, after the close of the market on 
Thursday, May 5, 2022. Management will host a conference call and webcast at 
4:30 PM EDT to discuss the financial results and answer questions.

Thursday, May 5, 2022, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13728177
Webcast: electroCore Earnings Webcast

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

Contact:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital

Release – PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results



PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

Research, News, and Market Data on PDS Biotech

 

FLORHAM PARK, N.J., April 28, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing molecularly targeted cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that the Company will release financial results for the first quarter of 2022 on Wednesday, May 11, 2022, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

Wednesday, May 11, 2022, 8:00 AM EDT
Domestic: 877-407-3088
International: 201-389-0927
Conference ID: 13728184
Webcast: PDS Biotech Earnings Webcast

After the live webcast, the event will be archived on PDS Biotech’s website for six months.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms.

Our Versamune®-based molecularly targeted products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate, and ovarian cancers. 

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital

Trump Media De-Spac in Face of Musk Twitter Purchase


Image Credit: Diverse Stock Photos (Flickr)


The DWAC SPAC Acquiring Trump Media Keeps Investors on Edge

 

When a SPAC, such as Digital World Acquisition Corp. (DWAC), soon to become Trump Media & Technology Group (TMTG), enters the DeSPAC phase, the terms are set, but the world keeps turning. For this reason, investors and potential investors need to continue to monitor events impacting the industry and the company to be acquired. There have been many surprises since October for DWAC shareholders, the past three days have been particularly challenging for investors to unravel.


Background

Since Trump Media agreed to be acquired on October 20, 2021, much has happened that could impact the company and the industry. These include an SEC probe of the deal, post-pandemic changes in users’ lifestyles, a frigid national relationship developing with Russia, and Twitter agreeing to be taken private by a “free speech” purchaser. Even when a SPAC’s formal ownership change hasn’t yet taken place, understanding the stock’s outlook (and future versions of the company) is as important as any other public company, perhaps a little more complex.

 


Source: Koyfin

The Trump Media example is star-studded and has faced renewed uncertainty within the past two weeks. When Elon Musk succeeded in striking a deal to take Twitter private for the purpose of providing a “platform for free speech around the globe,” this instantly created competition for the media start-up being acquired by the Digital Media SPAC.  And it has caused gyrations in the price for the pre-merger stage for DWAC, which hit a 30-day low of $33.25 the day of the announcement (April 25) and then bounced significantly up to $47.36 as the future owner of the well-established Twitter demonstrated through various Tweets, that the companies are not really competitors, but instead exist for similar purposes.

On April 27 Elon Musk gave DWACs share price a boost when he Tweeted “Truth Social is currently beating Twitter & TikTok on the Apple Store.” While Musk envisions Twitter as providing a platform for free speech around the globe, the smaller start-up social platform claims to be, “a free-speech haven without viewpoint discrimination or oppressive censorship.” If Musk is true to his stated purpose, the two may actually complement each other.

Take-Away

Investing in a SPAC with the trust that the acquisition company can steer the capital into a purchase you may not otherwise have been fortunate enough to participate in, is one reason for investors to allocate assets to SPACs. When the target has been identified and the deal requires a choice by the investor, information is important. Should an investor decide to be part of the deal and hold the acquisition company during the De-SPAC stage, they need to continue to be alert as to changes in the industry and the now identified company to be merged.

A perfect example of the challenges is the DWAC / Twitter scenario that DWAC shareholders are faced with. The company to be acquired seems to have had one of its mega-competitors working to steer its product line even closer to that of the small fledgling company.

Channelchek helps keep investors in smaller companies informed with quality research, insightful articles, and SPACtrac for select SPACs. Register for emails here.

As for the former President’s comments, Trump said, 

“I am not going on Twitter, I am going to stay on TRUTH,” Prior to the purchase the former President stated, “I hope Elon buys Twitter because he’ll make improvements to it and he is a good man” 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Content



Investors Watch Media SPAC Stay in the Green as Markets Falter



De-SPAC – The Final Phase of a Special Purpose Acquisition Company





SPACtrac Report – Forbes Global Media Holdings



Capstar Special Purpose Acquisition Corp. Class A (Video)

 

Sources

https://www.prnewswire.com/news-releases/rumble-sets-new-all-time-records-across-all-key-performance-measures-301519357.html

https://www.sec.gov/Archives/edgar/data/0001849635/000110465921128231/tm2130724d1_ex99-1.htm

https://www.prnewswire.com/news-releases/elon-musk-to-acquire-twitter-301532245.html

https://www.cbsnews.com/news/trump-media-technology-group-investors-digital-world-acquisition-spac/

 

Stay up to date. Follow us:

 

What Sectors Do Best With a Strong Dollar?


Image Credit: Pratkxox (Flickr)


Using Current Dollar Strength to Refine Your Watch List

 

The U.S. dollar is up 8.1% vs. its trading partners (DXY) thus far in 2022 (April 28). Over the past 20 years, when the U.S. dollar rose, U.S. stock indexes have shown a positive correlation. To date, this has not happened in 2022. As measured by the S&P 500, stocks are down about 12% this year. A reversion to a more statistical correlation could bring stocks up, the dollar down, or possibly both.

Of course, within the universe of stocks, there will be some investments that are much more positively correlated to the dollar and those that have demonstrated themselves to have a negative correlation. When the currency has a strong and clear direction, it may make sense to look into stocks in the sectors that have a higher probability of taking their cue from the dollar.


Dollar Value Moves Some Stock Prices

Any country’s currency can gain in value relative to other currencies. This happens when there is increased global demand for the currency, or when there is a reduction in the supply of currency available. 

There is a high propensity that an increase in the dollar’s value will coincide with a rise in U.S. market indices since U.S. stocks are denominated in dollars.  At a minimum, they should outperform foreign markets.


Source: Koyfin

As mentioned above, a way to magnify any effect is to understand the sectors that benefit from a weak or strong native currency and then research stocks within that industry for selection. Often the smaller more concentrated companies provide an even greater effect.

Manufacturing businesses that rely heavily on raw materials, or commodities and get these products from overseas (steal, semi-precious metals, minerals, etc.) will benefit from paying in or exchanging from the stronger currency. This has the impact of reducing relative costs and helping the bottom line. Stocks do better with a growing bottom line.

Importers also do well in a strong and rising dollar scenario. The reason is if the cost of goods is paid for in stronger dollars they are lower in price because they are manufactured and sold based on a depreciated currency.

 

Take-Away

The values of American stocks tend to increase along with the demand for U.S. dollars; they have a positive correlation.

One explanation for this relationship is foreign investment. As more investors place their money in U.S. equities, they are required to first buy U.S. dollars to purchase American stocks, causing the indexes to increase in value. So the stocks are actually causing the increased demand for the dollars. The inverse could be true as well. Continued dollar strength may cause more people to convert to dollars and they then keep the currency invested in U.S. markets, thus driving up equity prices.

 

 

Suggested Reading



Money Supply is Like Caffeine for Stocks



Financial Protection Bureau Has New Supervisory Powers





Why Good Economic Numbers Can Cause a Selloff



How PPI Impacts CPI Numbers

 

Sources

www.koyfin.com

 

Stay up to date. Follow us:

 

ACCO Brands (ACCO) – Sales and Profits Exceed Management Expectations For 1Q22

Wednesday, April 27, 2022

ACCO Brands (ACCO)
Sales and Profits Exceed Management Expectations For 1Q22

ACCO Brands Corporation designs, manufactures, sources, markets, and sells office products, academic supplies, and calendar products primarily in the United States, Canada, Northern Europe, Brazil, Australia, and Mexico. It operates through three segments: ACCO Brands North America, ACCO Brands EMEA, and ACCO Brands International. The company offers office products, such as stapling, binding and laminating equipment, and related consumable supplies, as well as shredders and whiteboards; and academic products, including notebooks, folders, decorative calendars, and stationery products. It also provides private label products, as well as business machine maintenance and repair services. The company offers its business, academic, and calendar product lines under the Artline, AT-A-GLANCE, Derwent, Esselte, Five Star, GBC, Hilroy, Leitz, Marbig, Mead, NOBO, Quartet, Rapid, Rexel, Swingline, Tilibra, Wilson Jones, and other brand names. In addition, it designs, sources, distributes, markets, and sells accessories for laptop and desktop computers, and tablets comprising security products; input devices, such as presenters, mice, and trackballs; ergonomic aids, including foot and wrist rests; docking stations; and other personal computers and tablet accessories under the Kensington, Microsaver, and ClickSafe brand names. The company sells its products to consumers and commercial end-users primarily through resellers, including traditional office supply resellers, wholesalers, mass merchandisers, and retailers, as well as directly to consumers through on-line and direct mail. ACCO Brands Corporation is headquartered in Lake Zurich, Illinois.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    1Q22 Operating Results. ACCO reported Q22 revenue of $441.6 million, up 7.6% year-over-year and up 11.2% on a comparable basis, with all segments posting growth. We had forecast $420 million. Adjusted EPS was $0.11, compared to $0.10 last year. We had forecast adjusted EPS of $0.09.

    Growth Across All Segments.  ACCO experienced meaningful comparable sales growth across all segments. Both reported and comparable sales were driven by higher sales prices, a positive 6.4% impact, and higher volumes, up 4.7%. ACCO saw strong demand for school products, computer accessories, and business products. Adverse foreign exchange reduced net sales by $14.9 million, or 3.6% …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Engine Gaming and Media (GAME)(GAME:CA) – A Streamlined Path Toward Positive Cash Flow

Wednesday, April 27, 2022

Engine Gaming and Media (GAME)(GAME:CA)
A Streamlined Path Toward Positive Cash Flow

Engine Media Holdings Inc is engaged in esports data provision, esports tournament hosting, and esports racing. Its brand profile includes Eden Games, Allin sports, and UMG, and others. The company’s operating segments include E-Sports; Media and Advertising and Corporate and Other. It generates maximum revenue from the Media and Advertising segment. The Media and Advertising segment includes platform and advertising services provided to other broadcasters, primarily local tv and radio broadcasters.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Noblecon 18 highlights. Tom Rogers, Executive Chairman, and Lou Schwartz, CEO, outlined the new strategy of the company at Noblecon18 following important recent developments, considered to be shareholder friendly. To view this fireside chat which provided detail on its plan to streamlined operations and swing toward positive cash flow, click here.

    New strategy.  Recently Engine shifted its focus towards media and advertising, with a special focus on social influencer marketing. Importantly, the sector trends appear favorable, with the influencer marketing industry expected to grow at a 30% CAGR from 2021 to 2025. Management identified its differentiation from competitors in the growing live-streaming platforms and social media platforms …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Entravision Communications (EVC) – The One To Watch

Wednesday, April 27, 2022

Entravision Communications (EVC)
The One To Watch

Entravision Communications Corporation is a diversified Spanish-language media company utilizing a combination of television and radio operations to reach Hispanic consumers across the United States, as well as the border markets of Mexico. Entravision owns and/or operates 53 primary television stations and is the largest affiliate group of both the top-ranked Univision television network and Univision’s TeleFutura network, with television stations in 20 of the nation’s top 50 Hispanic markets. The Company also operates one of the nation’s largest groups of primarily Spanish-language radio stations, consisting of 48 owned and operated radio stations.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Noblecon 18 highlights. CEO, Chris Young, touched on several topics including the company’s digital and global transformation, attractive leverage position, the company’s high cash flow, its attractive Latino TV business, and recent expense reductions. The full replay of the presentation can be found here.

    Digital sales rep.  Over the last several years, the company’s acquisitions of businesses like Cisneros, Media Donuts, and 365 Digital, have transformed it into a digital-based media company. Many of the digital businesses focus on selling advertisements for social media platforms in emerging markets, like Latin America, South Africa, and the Pacific rim. Digital revenue now accounts for more than …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Baudax Bio (BXRX) – NobleCon 18 Presentation

Wednesday, April 27, 2022

Baudax Bio (BXRX)
NobleCon 18 Presentation

Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. Gerri Henwood, President and Chief Executive Officer, presented at the conference. The presentation highlighted continued ANJESO growth, reduced cash burn and pipeline progress of the Company’s Neuromuscular Blockers (NMBs) and NMB Reversal Agents. A replay of the presentation can be found here.

    ANJESO is growing.  Growth has been strong as Baudax Bio continues to win formularies, not only in regional hospitals and ambulatory surgery centers (ASCs), but also integrated delivery networks (IDNs) and national ASC groups. Highly positive clinical experience has helped account penetration …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

BioSig Technologies (BSGM) – NobleCon 18 Presentation

Wednesday, April 27, 2022

BioSig Technologies (BSGM)
NobleCon 18 Presentation

BioSig Technologies, Inc. is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. PURE EP is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EP System has received FDA 510(k) clearance and installed its first commercial sale in February 2021. The company looks to apply their unique bioelectronic technology across additional disease conditions, including nervous system disorders, auto-immune diseases, hypertension, and pain.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    NobleCon 18. Kenneth Londoner, Chairman and CEO, presented at the conference. The presentation highlighted the PURE EP market opportunity, growth in procedure usage, and commercialization strategy. A presentation replay can be found here.

    Expanding usage.  PURE EP has now been used in over 2200 procedures at 17 sites, showing sequential quarterly growth every quarter. This is a strong indication of demand and need for the technology, despite some pandemic headwinds. AFib is the fastest growing sector in cardiology, with one in four over the age of 60 having AFib, so need should only increase …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.